Liraglutide
Symbol Lg · MW 3751 Da
Daily GLP-1 receptor agonist for diabetes and chronic weight management.
- Discovered
- 1997
- Half-life
- 13 hours
- Approval
- FDA-approved (Saxenda, Victoza)
Quick facts
- Category
- Weight Loss
- Route
- Injectable
- Molecular weight
- 3751 Da
- Half-life
- 13 hours
- Discovered
- 1997
- Approval status
- FDA-approved (Saxenda, Victoza)
Reported effects
- Appetite control
- Glycemic control
- Cardio-metabolic benefit
Overview
Liraglutide is a GLP-1 receptor agonist peptide used for blood sugar control and chronic weight management. It works by mimicking glucagon-like peptide-1, a natural hormone that helps regulate insulin release, appetite, digestion, and blood glucose levels. Liraglutide supports weight loss primarily by helping people feel full sooner, stay full longer, and reduce overall food intake. It also slows gastric emptying, which can help improve appetite control throughout the day. As a weight loss peptide and diabetes medication, Liraglutide is one of the earlier GLP-1 therapies and helped pave the way for newer medications like Semaglutide and Tirzepatide.
Evidence context
Liraglutide evidence summary
Human clinical evidence
Liraglutide has an approval context listed in the Peptidic database. Approved use still depends on the specific indication, formulation, labeling, and clinician guidance.
Animal, preclinical, or formulation evidence
Liraglutide may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for Liraglutide as FDA-approved (Saxenda, Victoza). The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- 0.6–3 mg
- Typical Frequency
- Once daily
Dosing depends on the approved indication, formulation, titration schedule, and clinician guidance. This page is educational and not a substitute for medical advice.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on Liraglutide.
Internal links
Related peptides
Frequently asked questions
What category is Liraglutide in?
Liraglutide is listed in the Weight Loss category on Peptidic.
What route is Liraglutide associated with?
Liraglutide is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is Liraglutide approved?
Peptidic lists the approval status for Liraglutide as: FDA-approved (Saxenda, Victoza). Approval details can vary by indication and jurisdiction.
Interested in Liraglutide?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01